Results 51 to 60 of about 3,401,781 (173)

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

open access: yesBlood, 2020
Introduction: CRS is a potentially life-threatening toxicity observed following T cell-redirecting therapies. CRS is associated with elevated cytokines, including IL6, IFNγ, TNFα, IL2 and GM-CSF. Glucocorticosteroids (GC) and the IL6 receptor blocking antibody tocilizumab (TCZ) can reduce CRS severity; however, CRS may still occur and limit the ...
Geoffrey L Uy   +45 more
openaire   +1 more source

An in vitro co-culture model with CAR-T cells, antigen-presenting cells, and tumor cells to evaluate CAR-T cell-induced cytokine release syndrome

open access: yesFrontiers in Cellular and Infection Microbiology
ObjectiveChimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in hematological malignancies. However, it can also cause severe systemic toxicity, known as cytokine release syndrome (CRS).
Yuke Ren   +14 more
doaj   +1 more source

Therapeutic Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19

open access: yesFrontiers in Pharmacology, 2021
Treatment of the cytokine release syndrome (CRS) has become an important part of rescuing hospitalized COVID-19 patients. Here, we systematically explored the transcriptional regulators of inflammatory cytokines involved in the COVID-19 CRS to identify ...
Clarissa S. Santoso   +6 more
doaj   +1 more source

Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy

open access: yesSignal Transduction and Targeted Therapy, 2021
Cytokine release syndrome (CRS) embodies a mixture of clinical manifestations, including elevated circulating cytokine levels, acute systemic inflammatory symptoms and secondary organ dysfunction, which was first described in the context of acute graft ...
Xia Li   +4 more
doaj   +1 more source

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

open access: yes, 2022
•Durable responses to axi-cel are seen in patients who do not develop cytokine release syndrome .•In patients receiving axi-cel, grade 1 to 2 cytokine release syndrome is associated with best outcomes.•Patients with grade 3 to 5 experience the worst ...
Andreadis, Charalambos   +51 more
core   +1 more source

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

open access: yes, 2021
We evaluate the risk, characteristics and biomarkers of treatment-emergent cytokine release syndrome (CRS) in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received APVO436 during the dose-escalation
Paul J. Shami   +19 more
core   +1 more source

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies

open access: yesFrontiers in Immunology, 2020
Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider ...
Elizabeth L. Siegler   +5 more
doaj   +1 more source

Supplementary Figure S13 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S13. A. 3D in vitro experimental setup. Human PBMCs and SU-DHL-8 tumor cells were co-cultured in a ratio of 5:1 and treated with 0.01 nM CD20-TCB in the presence or absence of 5 μg/mL adalimumab for 24 hrs. Supernatant from the co-cultures was transferred to the bottom channel of the Mimetas OrganoPlate®.
Marina Bacac   +22 more
openaire   +1 more source

Supplementary Table S3 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Table S3. Specification of reagents for flow cytometry (HUVEC staining)</p>
Marina Bacac   +22 more
openaire   +1 more source

Supplementary Figure S11 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S11. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform. A. UMAP plots of neutrophils colored by treatment. B. UMAP plots showing IL-1β (IL1B), IL-1Ra (IL1RN), IL-6 (IL6), IP-10 (CXCL10), IL-8 (CXCL8), TNF-α (TNF), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4)
Marina Bacac   +22 more
openaire   +1 more source

Home - About - Disclaimer - Privacy